Dr. David Shlaes has written numerous times on "pull incentives" to encourage new antibiotic discovery, and why professional societies (like the Infectious Diseases Society of America and the AMA) aren't providing enough input to emphasize the importance of emerging bacterial resistance. Today our ACSH advisor expands on both topics.
The United States is not the only country where drug pricing is disjointed. Referring to Europe, ACSH advisor Dr. David Shlaes writes that it is "definitely still a tapestry of nations or even the Wild West." Especially in the world of antibiotics.
The science of discovering and developing new antibiotics is difficult enough. But antibiotics present an additional, unique problem: economics. It is very difficult for a pharmaceutical company to even recoup its R&D costs because of a small market, which is mostly hospital use. Some kind of subsidy is necessary. ACSH advisor Dr. David Shlaes examines whether Medicare can help, and to what degree.
Antibiotics expert Dr. David Shlaes has been fighting two very tough fights for more than three decades. One is against increasingly dangerous antibiotic-resistant bacteria; the other, against complacency. This American Council advisor is deeply concerned that antibiotic research and development is not even remotely adequate for keeping up with the bugs.
American Council advisor, and infectious disease expert Dr. David Shlaes has been writing a blog called "Antibiotics—the Perfect Storm" since 2009. Today, he features a guest blogger, Dr.Tamar Ghosh, who leads the Longitude Prize for the Innovation Lab at Nesta, a charity that is devoted to increasing the innovation capacity of the UK. Dr. Ghosh writes about the biggest science prize in the UK:
Dr. David Shlaes, American Council advisor and infectious disease expert, has been blogging about antibiotics since 2009. His latest entry concerning the FDA is rather encouraging, but it's also a bit disturbing.
We at ACSH have been writing about the dire situation we face because of antibiotic resistance for years. Both Dr. Josh Bloom and ACSH advisor Dr. David Shlaes a world renowned expert in the field have written many times about the looming antibiotic crisis, a time when common infections that were previously treatable are no longer so
We at ACSH are fortunate to have amongst our erudite Advisors Dr. David Shlaes, one of the world experts in the fields of both antibiotic research and FDA regulatory policies. Shlaes has been intimately involved with the FDA, which he has both criticized and worked with, trying to prevent us from entering a pre-penicillin age, when there were no effective treatments for bacterial infections.
Yesterday, we took Zeke Emanuel s and his New York Times op-ed to task for a variety of reasons. Today, ACSH advisor David Shlaes, in his blog, Antibiotics-The Perfect Storm, takes a more nuanced look at an alternative way to refill the antibiotic pipeline without dangling big prize money in front of companies that succeed in coming up with a new class of antibiotics (whatever that means).
There is an op-ed in today s New York Times written by former Obama administration health guru Dr. Ezekiel Emanuel, which supposedly addresses the dire need for new antibiotics which is both wrong and misleading.
We at ACSH have been beating this drum for years: The world is getting into serious trouble bad enough to make Ebola seems like athlete s foot because of the proliferation of antibiotic-resistant bacteria coupled with a sharp decline in drug discovery research in this area. Some public health officials believe that this is the single biggest threat to global human health one that could take us back to the days before the discovery of penicillin, when death from common diseases such as pneumonia and strep throat was common.
We have often written about the antibiotic crisis in which we now find ourselves. The main problem standing in the way of progress in the development of new, effective antibiotics seems to be that it s very expensive, and companies are not incentivized to invest time and money in this area. A blockbuster drug (e.g. Lipitor) has to